IXICO plc (AIM:IXI), a provider of neuroscience precision medicine and biomarker analytics, announced on Monday that it has secured a global Phase 3 clinical trial imaging contract worth more than GBP3.5m over four years with a multinational pharmaceutical company developing a treatment for Huntington's Disease.

This agreement reinforces IXICO's established position in HD, where its AI-driven biomarker analytics, image analysis capabilities and clinical trial management are widely recognised across the research ecosystem. Demand for HD expertise is accelerating as progress in therapeutic development continues.

The win extends the company's commercial momentum and supports the execution of its 'Innovate, Lead, Scale' strategy aimed at global growth. IXICO operates as a specialist imaging CRO with a 20-year track record, supporting hundreds of neurological trials through its proprietary platform and global network of imaging centres.